Your session is about to expire
← Back to Search
Prostaglandin Analog
Travoprost Implant vs Timolol Drops for Glaucoma
Phase 3
Waitlist Available
Research Sponsored by Glaukos Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Zero to three preoperative ocular hypotensive medications
Diagnosed with open-angle glaucoma or ocular hypertension.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Study Summary
This trial is testing two different intraocular implants to see if either is more effective than Timolol Maleate Ophthalmic Solution in reducing intraocular pressure in subjects with open-angle glaucoma or ocular hypertension.
Who is the study for?
This trial is for people with open-angle glaucoma or ocular hypertension. Participants can have a cup-to-disc ratio of up to 0.8 and may be using up to three medications to lower eye pressure. Those with active corneal inflammation, edema, or retinal disorders unrelated to glaucoma cannot join.Check my eligibility
What is being tested?
The study is testing two versions of a travoprost-releasing intraocular implant against Timolol Maleate Ophthalmic Solution (a standard treatment) in reducing high eye pressure caused by glaucoma or hypertension. It's a Phase III trial where one group gets the implants and another uses timolol drops.See study design
What are the potential side effects?
Possible side effects include discomfort from the sham surgery or implant procedure, potential irritation from the eye drops, and any typical risks associated with intraocular devices such as infection or changes in vision.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am using up to 3 eye pressure-lowering medications.
Select...
I have been diagnosed with open-angle glaucoma or high eye pressure.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months Postoperative
Secondary outcome measures
Mean IOP (Control Group vs. Each Implant Group) Through 12 Months Postoperative
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Implant Group 2Experimental Treatment1 Intervention
G2-TR intraocular implant containing travoprost 75 mcg with low elution rate, plus postoperative placebo eye drops.
Group II: Implant Group 1Experimental Treatment1 Intervention
G2-TR intraocular implant containing travoprost 75 mcg with high elution rate, plus postoperative placebo eye drops.
Group III: Control GroupActive Control1 Intervention
Sham surgery + active-comparator eye drops
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Ocular Hypertension include prostaglandin analogs like Travoprost, which increase the outflow of aqueous humor, thereby reducing intraocular pressure (IOP). This is particularly important as elevated IOP is a major risk factor for glaucoma.
Other treatments include beta-blockers, which decrease aqueous humor production, and alpha agonists, which both decrease production and increase outflow. Carbonic anhydrase inhibitors also reduce aqueous humor production.
Understanding these mechanisms helps in choosing the most effective treatment with minimal side effects, tailored to the patient's specific needs.
Bimatoprost effects on aqueous humor dynamics in monkeys.
Bimatoprost effects on aqueous humor dynamics in monkeys.
Find a Location
Who is running the clinical trial?
Glaukos CorporationLead Sponsor
65 Previous Clinical Trials
8,450 Total Patients Enrolled
5 Trials studying Ocular Hypertension
1,167 Patients Enrolled for Ocular Hypertension
Kerry Stephens, O.D.Study ChairGlaukos Corporation
4 Previous Clinical Trials
1,229 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am using up to 3 eye pressure-lowering medications.I have been diagnosed with open-angle glaucoma or high eye pressure.I have active inflammation or swelling in my cornea.I have a retinal disorder that is not related to glaucoma.
Research Study Groups:
This trial has the following groups:- Group 1: Implant Group 1
- Group 2: Implant Group 2
- Group 3: Control Group
Awards:
This trial has 2 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger